Gatifloxacin pulled from last major market
This article was originally published in Scrip
Executive Summary
Kyorin Pharmaceuticaland Dainippon Sumitomo Pharma(DSP) have voluntarily discontinued all sales of the antibacterial Gatiflo (gatifloxacin) in Japan. The decision was prompted by continued reports of abnormal blood glucose levels during the use of the oral fluoroquinolone, which the firms said could not be disassociated from its use.